Technetium 99m sestamibi in multiple myeloma.
نویسندگان
چکیده
bone involvement. Destruction is mediated through normal osteoclasts, which respond to local osteoclast-activating microenvironment [7]. Technetium-99m 2methoxyisobutylisonitrile (TC-99m MIBI) is a lipophilic agent that accumulates within living malignant cells due to the higher transmembrane electrical potential as a consequence of the higher metabolic rate than in the surrounding normal cells [2]. It has been reported to be useful in detecting disease lesions in multiple myeloma [1,10,17,19,27]. In comparative studies, Tc-99m MIBI scintigraphy proved to be superior to skeletal X-ray survey in detecting bone and bone marrow involvement [8,9]. In myeloma, the isotope bone scan may be falsely negative because of purely osteolytic lesions, but may not be completely normal if there is some osteoblastic activity, particularly in relation to pathological fracture. Other radiopharmaceuticals which have shown promise in the investigation of myeloma include gallium-67, Tc-99m tetrofosmin and thallium-201 [10,29]. Tc-99m-MIBI has been reported to be distributed as a diffuse and/or focal uptake in bone marrow of patients with active myeloma disease. Furthermore, a semiquantitative score based on the extension and intensity of the diffuse uptake on whole–body scan showed a direct correlation with plasma cell infiltration, clinical status and stage of the disease [19]. In patients undergoing chemotherapy, the findings of baseline Tc-99m MIBI scintigraphy are strongly correlated with the clinical outcome at follow-up. These results suggested a potential role of Tc-99m-MIBI in the follow-up of patients with multiple myeloma [22].
منابع مشابه
Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease.
BACKGROUND AND OBJECTIVES Technetium-99m 2-methoxy-isobutyl-isonitrile ((99m)Tc-sestamibi) has recently been proposed as a potential tracer in patients with multiple myeloma (MM), as its increased uptake in the bone marrow has been reported as indicator of myeloma activity. We evaluated the role of (99m)Tc-sestamibi scintigraphy in the detection of myeloma bone disease in MM and related gammopa...
متن کاملHepatic and splenic uptake of Tc-99m HDP in multiple myeloma: additional findings on Tc-99m MIBI and Tc-99m sulfur colloid images.
The authors present a case of multiple myeloma with intense hepatic and splenic uptake on Tc-99m HDP bone scan and discuss its clinical implications and possible uptake mechanisms. Tc-99m MIBI and Tc-99m sulfur colloid were used to demonstrate bone marrow involvement and focal lesions of multiple myeloma.
متن کاملMultiple myeloma in a patient with suspected hyperparathyroidism
Multiple myeloma (MM) is a clonal B-lymphocyte neoplasm of terminally differentiated plasma cells. Imaging modalities which allow the recognition of the effects of myeloma cells on the skeletal system have been utilized for a long time. Herein, we represent a patient with generalized osteoporosis and hypercalcemia, who was referred for parathyroid scan, in whom the widespread bone marrow techne...
متن کاملTc 99m Sestamibi Scanning in Multiple Myeloma--a New look with SPECT-CT.
UNLABELLED A variety of diagnostic tools including biochemistry, radiological imaging bone marrow studies and recently metabolic imaging with FDG PET are used for assessment of disease extent in myeloma. AIM To evaluate the role of metabolic imaging with Tc99m Sestamibi (Mibi) SPECT-CT in Multiple myeloma. MATERIALS AND METHODS Patients in various stages of Myeloma were scanned after 20mCi ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Radiology
دوره 234 1 شماره
صفحات -
تاریخ انتشار 2005